Johnson & Johnson (JNJ) Eyes Ollin Biosciences, Is It 19% Overvalued?
J&J Pushes Into Retinal Disease With $2.2 Billion Ollin Deal
J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences
Johnson & Johnson Stocks Edge Higher on $2.2 Billion Ollin Eye Deal
J&J bets $2.2B on Ollin’s vision loss drug
Johnson & Johnson Agrees to Buy Ollin Biosciences in Up to $3.33 Billion Deal
Why Is Johnson & Johnson (JNJ) Showcasing New Blood Cancer Data At ASH?
Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology
ETFs Are Net Sellers of Johnson & Johnson (JNJ) on Thursday
Johnson & Johnson Confirms It Will Acquire Ollin Biosciences To Increase Exposure To Serious Eye Disease Treatments For Initial Sum $2.2B And Up To ~$1.125B In Potential Milestones
J&J in talks to buy eye disease biotech Ollin for $3.4 bln, FT reports
Financial Times Reported Sunday J&J In Talks to Buy Eye Disease Biotech Co Ollin For Up To $3.4B
Did Bipolar Drug Win Just Shift JNJ's Investment Narrative?
ETFs Are Buying Johnson & Johnson (JNJ) on Nov. 11
Johnson & Johnson (JNJ) Backs New Cancer Device And Leads $100 Million Depression Bet
Johnson & Johnson (JNJ) Up 10.4% Since Last Earnings Report: Can It Continue?
Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?
Johnson & Johnson Reports Favorable Data For Bipolar Study
Is Johnson & Johnson (JNJ) Below Fair Value On Cash Flow?
J&J's Oncology Sales Surge So Far in 2026: What Lies Ahead?
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.